| Ovarian cancer is the most common cause of female cancer mortality in women. Most patients with epithelial ovarian carcinoma present with advanced disease at the time of diagnosis. Although primary cytoreductive surgery or debulking procedure followed by systemic chemotherapy is the standard treatment protocol used in the management of ovarian cancer, the overall five-years survival is only about 30%. This study is to evaluate several "hotspot" of treatments for ovarian carcinoma, such as retroperitoneal lymphadenectomy in first cytoreductive surgery, neoadjuvant chemotherapy in patients with advanced epithelial ovarian carcinoma, secondary cytoreductive surgery and second-line chemotherapy in patients with recurrent epithelial ovarian carcinoma. It comprises data on ovarian cancer from the Department of female tumor of Guangxi Tumor Hospital and a large number of studies in ovarian cancer have been reviewed following the standard of evidenced-based medicineAnalysis prognostic factors of ovarian cancerOBJECTIVE: The purpose of this study was to determine prognostic factors that have an impact on overall survival. METHODS: A retrospective review was performed of 313 patients treated between 1985 and 1998 at the Department of female tumor of Guangxi Tumor Hospital. Survival was calculated by Kaplan-Meier method and comparison was performed using Log-rank test. Independent prognostic factors were identified by the COX proportional hazards regression model. RESULTS: Multivariate analysis showed that stage, the size of residual tumor, retroperitoneal lymphadenectomy and the number of courses of chemotherapy were the most important prognostic factors.Evidence-based research on clinical value of retroperitoneal lymphadenectomy for ovarian cancerOBJECTIVE: To explore the clinical value of retroperitoneal lymphadenectomy for ovarian cancer. METHODS: A retrospective review was performed of 361 patients treated between 1985 and 2002 at the Department of female tumor of Guangxi Tumor Hospital. On the other hand, a large number of studies on retroperitoneal lymphadenectomy in first cytoreductive surgery have been reviewed. RESULTS: The overall 5-year survival was 56.6% and 48.2% for patients who did and did not undergo lymphadenectomy, respectively (P < 0.05). But the survival rate could not be improved through retroperitoneal lymphadenectomy in the patients with early stage (P > 0.05). Among patients with advanced stage who undergo lymphadenectomy , 5-year survival was 76.5% and 38.5% for patients whose size of residual tumor < 2 cm and >r =2cm, respectively (P < 0.05). Multivariate analysis showed that stage, residual tumor, retroperitoneal lymphadenectomy and the number of courses of chemotherapy is the prognostic factors in patients with epithelial ovarian cancer. CONCLUSIONS: Although retroperitoneal lymphadenectomy could improve the survival rate, it should be carried out selectively. However, there is evidence-based result showed that retroperitoneal lymphadenectomy could improve survival rate to a patient with early stage and advanced stage carcinoma.Evidence-based research on clinical value of neoadjuvant chemotherapy for ovarian cancerOBJECTIVE : The purpose of this study was to assess the survival benefit of neoadjuvant chemotherapy (NAC) in patients with FIGO stage â…¢ or IV epithelial ovarian cancer. METHODS: In patients treated for stage â…¢ or IV ovarian epithelial malignancies at the Department of female tumor of Guangxi Tumor Hospital between 1985 and 1998, 94 patients had a diagnosis of advanced ovarian carcinoma. For this group, the long-term outcome was compared between 68 patients receiving conventional adjuvant chemotherapy following standard surgery and 26 patients treated with NAC followed by a cytoreductive surgery. On the other hand, a large number of studies on neoadjuvant chemotherapy in stage â…¢ or IV epithelial ovarian cancer have been reviewed. RESULTS: In a total of 94 patients with histologic types of epithelial ovarian malignancy, the overall 5-year survival was 21.6% a...
|
PDF Full Text Request